Dextrose And Sodium Chloride
RxNorm 244098· DEXTROSE AND SODIUM CHLORIDE· INTRAVENOUS
B. Braun Medical Inc.
Indications and usage
INDICATIONS AND USAGE These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes, calories and water for hydration.
Dosage and administration
DOSAGE AND ADMINISTRATION These solutions are for intravenous use only. Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy. When a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation. Carefully avoid infiltration. In the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of fluid containing 0.9% sodium chloride (154 mEq each of sodium and chloride). Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Pediatric Use There is no specific pediatric dose. The dose is dependent on weight, clinical condition, and laboratory results. See WARNINGS and PRECAUTIONS .
Warnings
WARNINGS The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration. Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. Infusion of isotonic (0.9%) sodium chloride during or immediately after surgery may result in excessive sodium retention. Use the patient's circulatory system status as a guide. Excessive administration of potassium-free dextrose solutions may result in significant hypokalemia. Serum potassium levels should be maintained and potassium supplemented as required. Solutions containing dextrose and low electrolyte concentrations should not be administered simultaneously with blood through the same infusion set because of the possibility of pseudoagglutination or hemolysis.
Contraindications
CONTRAINDICATIONS These solutions are contraindicated where the administration of sodium or chloride could be clinically detrimental. Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.
Pregnancy
Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with Dextrose and Sodium Chloride Injections USP. It is also not known whether Dextrose and Sodium Chloride Injections USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose and Sodium Chloride Injections USP should be given to a pregnant woman only if clearly needed.
Nursing mothers
Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Dextrose and Sodium Chloride Injections USP are administered to a nursing woman.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- vomiting39
- nausea34
- hyponatraemia28
- ascites27
- constipation27
- sepsis27
- abdominal distension26
- abdominal pain26
- general physical health deterioration25
- off label use25
- appendicitis24
- appendicolith24
- ventricular fibrillation24
- anaemia23
- cardiogenic shock23
- multiple organ dysfunction syndrome22
Adverse reactions (label)
ADVERSE REACTIONS Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. Too rapid infusion of hypertonic solutions may cause local pain and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a small bore needle is recommended. (See DOSAGE AND ADMINISTRATION .) Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential. Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume. If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect. The physician should also be alert to the possibility of adverse reactions to drug additives diluted and administered from the plastic container. Prescribing information for drug additives to be administered in this manner should be consulted. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.
KR · 한국Products in Korea (55)
- 뮤로128점안액2%(염화나트륨)(주)바슈헬스코리아
- 뮤로128점안액5%(염화나트륨)(주)바슈헬스코리아
- 페스비강분무액(염화나트륨)(주)엔터팜
- 페스비강분무액(염화나트륨)(주)엔터팜
- 페스리틀비강액(염화나트륨)(소아용)(주)엔터팜
- 페스리틀비강액(염화나트륨)(소아용)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 페스시누클린즈분무액(염화나트륨)(주)엔터팜
- 대한관류용멸균생리식염수대한약품공업(주)
- 대한3%염화나트륨액대한약품공업(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 피스코점비액(염화나트륨)동아에스티(주)
- 씨알알티에스에이취비아이씨삼십오용액비브라운코리아(주)
- 씨알알티에스에이취비아이씨삼십오용액비브라운코리아(주)
View more: Full FDA label on DailyMed →Label effective 20240402